Share this video  

ESMO Breast 2020 | HER2-E pCR with anti-HER2-based neoadjuvant therapies

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discusses a meta-analysis that validated the association of the HER2-E subtype with pathological complete response (pCR) following anti-HER2-based neoadjuvant treatments with or without chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).